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Abstract 
 
Introduction 
Prostate cancer is common and the incidence is increasing, but more men are living longer after 
diagnosis, and die with their disease rather than of it. Nonetheless, specific and substantial physical, 
sexual, emotional and mental health problems often lead to a poor quality of life. Urology services 
increasingly struggle to cope with the demands of follow-up care, and primary care is likely to play the 
central role in long-term follow-up. The present phase II trial will evaluate the feasibility and 
acceptability of a nurse-led, person-centred psycho-educational intervention, delivered in community 
or primary care settings. 
Methods and analysis 
Prostate cancer survivors diagnosed in the last 9-48 months and currently biochemically stable will be 
identified from hospital records by their treating clinician. Eligible men would have either completed 
radical treatment, or would be followed up with PSA monitoring and symptom reporting. We will 
recruit 120 patients who will be randomised to receive either an augmented form of usual care, or an 
additional nurse-led intervention for a period of 36 weeks. Following the health policy in Wales, the 
intervention is offered by a key worker, is promoting prudent healthcare, and is using a holistic needs 
assessment. Outcome measures will assess physical symptoms, psychological wellbeing, confidence in 
managing own health, and quality of life. Healthcare service use will be measured over 36 weeks. 
Feedback interviews with patients and clinicians will further inform the acceptability of the 
intervention. Recruitment, attrition, questionnaire completion rates and outcome measures variability 
will be assessed and results will inform the design of a future phase III trial and accompanying 
economic evaluation. 
Ethics and dissemination 
Ethics approval was granted by Bangor University and North Wales REC (13/WA/0291). Results will be 
reported in peer-reviewed publications, at scientific conferences, and directly through national cancer 
and primary care networks. 
Trial registration: ISRCTN 34516019  
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Introduction 
 
Prostate cancer is the most common cancer for men in the UK (second worldwide), and many 
survivors experience long-lasting physical and psychological needs. Over the last 20 years in the UK, 
incidence rates have doubled, but mortality rates have dropped by a quarter.[1-2] Common physical 
symptoms are related to sexual function, urinary incontinence,[3] bowel symptoms,[4] hot flushes and 
the risk of bone fracture.[5] The management of chronic co-morbid conditions (e.g., cardio- and 
cerebrovascular disease, hypertension, diabetes) often further increases the level of need, and about 
two thirds of prostate cancer patients are expected to have at least one major comorbidity.[6-8] 
Psychological distress is also significant, and most prostate cancer survivors require prompt 
information about treatment outcomes and its impact on daily living.[9] The diagnosis and treatment 
toxicities also affect the patients’ immediate families,[10] particularly through psychological distress 
related to anxiety, depression,[11-12] and psychosexual problems.[13] Thus, the assessment and 
management of the adverse treatment effects, related psychosocial needs (also affecting their 
partners), and the impact on the management of other comorbid conditions is for many patients 
complex and prolonged. 
Current usual care and evidence base. Prostate cancer patients are normally followed-up in 
out-patient clinics in hospital for up to five years, to monitor and manage the risk of recurrence and 
the physical symptoms following treatment.[14] However, current practice is not underpinned by 
robust evidence, and is notoriously variable between hospitals.[15] In the absence of reliable empirical 
evidence, the NICE guidelines recommend that unless significant treatment complications develop, 
after 2 years, their follow-up care should take place out of hospital.[16] However, recommendations 
on the type of follow-up to be undertaken are notably missing from the guidelines. 
In the last decade and a half, attempts have been made to address the lack of empirical 
evidence regarding the efficacy and cost-effectiveness of prostate cancer follow-up. Early initiatives 
showed that by involving primary and community care, the utilisation of specialist care may be 
reduced, especially for the more elderly patients.[17]  Also, patients perceive they receive more care 
from the GP,[18] while their quality of life remains similar between hospital and primary care follow-
up. However, notable concerns were reported about the continuity of care, the miscommunication 
between hospitals and GPs, and the integration of PSA testing. A number of hospital based 
alternatives have been proposed, such as hospital group clinics,[19] nurse face-to-face and telephone 
clinics,[20-22] and e-health technology based follow-up.[23-25] Such approaches fail to address the 
issues about the capacity and scope of specialist secondary care teams, who may struggle to offer, 
assess and manage a holistic range of physical, psychosocial and educational needs of patients. 
Recently, improvements in e-health platforms facilitating the communication between hospital and 
primary care, especially surrounding the safe monitoring of PSA levels and cancer recurrence, have 
revived efforts to consider a primary-care-led model of follow-up.[26]  
Nurse-led interventions have been consistently shown to be effective in a range of diseases, 
from diabetes and depression [27-28], to various cancers[29] and, more specifically, when 
interventions were administered in primary care settings.[30] There is sufficient literature showing the 
gaps in care to argue for a more intensive approach initially,[31] and most emerging models include a 
nurse-led assessment of needs. There is evidence that increasing the cancer patients’ participation in 
care can reduce their psychosocial and information needs.[32] Self-management is now accepted as a 
potential solution for the complex needs of prostate cancer survivors,[33] but conclusive evidence is 
still needed regarding the design and delivery of such interventions. 
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Person-centred and prudent healthcare for prostate cancer survivors. Despite a tradition of 
predominantly disease-centred follow-up, the person-centred approach features highly in the UK 
health policy agenda. The 2004 NICE guidelines[34] recognised the complex needs of cancer survivors, 
and the Cancer Reform Strategy[35] set out to understand and address them. In Wales, the 
government’s Together for Health – Cancer Delivery Plan[36] directed Health Boards to assign a Key 
Worker to assess and record the clinical and non-clinical needs of cancer survivors in a personalised 
care plan and to ensure care is co-ordinated between hospital and community. The policy highlighted 
the need for new multidisciplinary models of follow-up to be developed and evaluated. Moreover, the 
Bevan Commission[37] recommended the application of prudent healthcare principles, such as: (1) 
offering early interventions, (2) promoting self-management, and the co-production of healthcare, (3) 
involving community assets in order to reduce the level of unmet need, (4) removing unnecessary 
processes (especially the duplication of support services), and (5) adopting services that achieve 
similar or better patient outcomes while using less expensive human and technical resources. Thus, for 
prostate cancer follow-up the government health policy directs towards a holistic and person-centred 
care, delivered safely and at the earliest opportunity outside of hospital, with the aim of empowering 
patients to take an active role in managing and improving their health. 
The present trial (TOPCAT-P) is addressing directly the growing capacity challenges facing 
hospital based services in the UK, by engaging primary and community care soon after the end of the 
prostate cancer treatment. The pilot trial PROSPECTIV[14, 38] served as the basis for the development 
of the present work. TOPCAT-P is expanding the personalised nurse-led intervention being piloted in 
PROSPECTIV in three significant areas: (1) the intervention (including the holistic needs assessment) is 
being offered irrespective of the patient-reported level of need; (2) the care planning documentation 
and sharing are updated in response to on-going changes to policy and practice; (3) all participants in 
the intervention and control arms will receive Macmillan written materials as part of usual practice. 
The manualised nurse-led psycho-educational intervention includes an exploratory and person-
centred holistic needs assessment, promotes self-management of symptoms, is delivered out-of-
hospital, and includes patients’ partners, carers, or close family members where necessary. The aim of 
the current pilot trial is to evaluate the feasibility and acceptability of the intervention, addressing the 
wider group of cancer survivors, using the novel holistic needs assessment and care planning tools. 
 
Methods and analysis 
 Trial design 
TOPCAT-P is a randomised two-arm parallel-group phase II external feasibility trial, comparing 
the effectiveness and cost effectiveness of a personalised, nurse-led, psycho-educational intervention 
versus the augmented version of usual care beginning to be delivered in North Wales. The present trial 
follows the new MRC guidelines for the development of complex interventions[39] by investigating the 
feasibility and acceptability of the intervention, the novel holistic needs assessment instruments, and 
enhanced information documenting and sharing procedure. This will be used to inform the design of a 
phase III trial that will assess the effectiveness and cost-effectiveness of the intervention. 
 Participant recruitment and consent 
Inclusion criteria. The Urology Clinical Nurse Specialist (CNS) will identify biochemically stable 
incident prostate cancer patients, 9-48 months post-diagnosis, from the multidisciplinary team (MDT) 
records in the Wrexham Maelor Hospital. They would have either received radical curative treatment 
(surgery, radiotherapy, or hormone therapy), or be followed-up with PSA monitoring and symptom 
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reporting, but deemed unlikely to receive curative treatment (watchful waiting). Notably, both 
patients currently followed-up in the hospital or in the community will be invited to participate in the 
study. 
Exclusion criteria. The study will exclude men suitable for curative treatment, but who choose 
to be monitored until proof of further progression (active surveillance). Also, palliative patients who 
are in the terminal stage of their disease or who lack the capacity to consent (as assessed by the 
referring clinician) will not be included. 
Sample size 
We intend to invite 300 patients to take part in the pilot trial and estimate a recruitment rate 
of approximately 40%. This will allow the recruitment of 120 participants (60 per trial arm – optimum 
for the randomisation procedure described below).[40] A maximum attrition rate of 50% will ensure at 
least 30 patients per arm will complete the trial. This will provide a satisfactory number of participants 
for estimating the variation within the sample (i.e., the standard deviation of the outcome measures), 
in order to inform the power calculation for a future phase III trial; which would be powered to detect 
clinically relevant changes in prostate related health and cost-effectiveness. 
 Randomisation 
Participants will be randomised individually to one of the two arms of the trial (usual care or 
nurse-led intervention), on a 1:1 basis and stratifying for age, (65 or under, 66 to 72, 73 to 80, over 
80), according to the Cancer Incidence Report 2007-2011.[41] The concealed allocation procedure will 
use a secure, off-site electronic system managed by the North Wales Organisation for Randomised 
Trials in Health (NWORTH) – a UKCRC fully registered trials unit. The system uses a sequential dynamic 
adaptive randomisation algorithm,[40] tuned to balance within stratification levels and overall, whilst 
maintaining an acceptable level of unpredictability. 
 Augmented usual care  
Patients in both arms of the study will continue to receive the usual care delivered outside of 
the trial, including any follow-up appointments (at the hospital or general practice). To account for the 
variable patterns of follow-up care, all contacts with healthcare professionals will be recorded in 
bespoke health service use diaries (CSRI). To reflect the changes to usual care being implemented in 
Wales, all patients will be offered in person, after providing informed consent (see Appendices 1 and 
2), a Macmillan Organiser[42] to help self-record and monitor any physical and psychological 
symptoms, as well as the results of relevant medical tests and medication taken. All patients will also 
be signposted to contact the local Macmillan information centre for information and advice regarding 
any cancer-related concerns, as well as to contact their GP or hospital team, if necessary, for 
appropriate medical support. 
 Intervention 
 Supplementary to augmented usual care, patients in the intervention arm will be offered an 
initial appointment with the research nurse for a holistic needs assessment, and tailored follow-up 
appointments as appropriate. Before the start of the intervention, the research nurse will complete 
the two day course ‘The detection of psychological distress in patients with cancer’ needed for NHS 
staff to qualify at Level 2 of the 4-tier model of Psychological Support.[34, 43] Additionally, through 
the Macmillan network, the nurse will complete three training modules routinely recommended for 
clinical staff delivering holistic needs assessments: “Maguire Advanced Communication Skills” 
training,[44] “Motivational Interviewing”, and “10-minute CBT”.[45-46] The intervention will make use 
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of dynamic personal care plans, and encourage self-management (empowering men to help 
themselves). Distinctly, the research nurse will use a comprehensive holistic needs assessment tool 
and care plan[47] – specifically exploring physical, emotional, spiritual, lifestyle and family aspects of 
cancer survivorship, together with an additional bespoke instrument developed in secondary care to 
monitor physical symptoms.[48] Following the assessment, the nurse will provide individualised 
information, advice, and support tailored to each patient, in order to help men improve their 
symptoms or cope better with symptoms they cannot improve. Patient referral to GP or secondary 
care and signposting to community or third sector support services will be made as appropriate. The 
holistic needs assessment will be documented and shared with both patients and, following consent, 
with their GP. If acute physical symptoms are identified or if disease recurrence is suspected these will 
be communicated directly to the secondary care team and GPs. All referrals to tertiary services will be 
documented in the secondary care cancer network information system (CaNISC) to be available to 
Oncology teams and facilitate seamless care between healthcare providers.[49] 
  The initial holistic needs assessment. The first appointment will be in person and will take 
place out of hospital, in the patient’s own primary care setting (by agreement with the general 
practice), at the local community hospital, or alternatively in a dedicated space at the research unit. 
Housebound patients will be offered home visits. The needs assessment will explore a comprehensive 
range of symptoms and concerns (see Table 1). The nurse will encourage patients to consider all the 
aspects of survivorship and specifically will explore symptoms and concerns beyond the formalised 
checklist. 
 
Table 1. Summary of holistic needs assessment  
Categories of need Symptom Summary of key assessment points 
1. Physical symptoms 1. Pain - type of pain, duration and level of pain 
2. Breathing problems - relevant comorbidities 
3. Appetite - appetite levels, weight loss, soreness to the 
mouth, difficulties with digestion, symptoms 
of nausea or vomiting 
4. Urinary function - lower urinary tract symptoms, bleeding, 
incontinence concerns, impact on everyday 
life (including psychological impact) 
5. Bowel function - loose stools, bleeding or incontinence, 
impact on everyday life (including emotional 
aspects) 
6. Mobility - limitations to mobility, relations to fatigue, 
impact on mood, general well-being and 
energy levels 
7. Fatigue - dietary intake, impact on mood, enjoyment 
of daily activities, quality of sleep, 
background stressors, fears or anxieties, 
relaxation therapies, organisation of daily 
activities 
8. Sexual function - erectile dysfunction, loss of libido, impact 
on relationship with partner, patients’ and 
partner’s feelings and anxieties 
9. Hot flushes - emotional impact, participation in social 
activities, relations with others 
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2. Emotional concerns, 
anxieties 
1. Depression - low mood, loss of interest everyday 
activities, depressive thoughts, behaviour 
changes, isolation, social relations, utility of 
mood record 
2. Anger - anger towards diagnosis, guilt at causing 
stress to partner or family, strain on 
relationships 
3. Fear of disease 
recurrence 
- lifestyle before diagnosis, hobbies, regular 
PSA monitoring 
4. Altered body 
image/sexuality 
- weight gain/loss, breast swelling, impact on 
mood and sexuality, behavioural changes, 
healthy nutrition, regular exercise 
5. Spirituality - loss of faith, meaning of life after diagnosis 
6. Financial concerns - loss of finance, insecurities about future 
earnings/costs, inability to afford past 
hobbies, financial support 
7. Lifestyle changes Travel insurance, planning of daily journeys, 
self-monitoring of symptoms 
8. Memory and 
attention 
Increased overall stress, general self-
confidence, change in sleep patterns 
 
The delivery of the intervention is based on the novel needs assessment instruments and care 
plan.[47, 50] Following the assessment, a range of person-tailored and symptom-specific management 
strategies will be taught. Physical and psychological needs will not be treated separately, but in 
relation to each other.[51] Thus, physical management techniques (e.g., pelvic floor exercises, double-
void technique) will be taught in the context of established cognitive-behaviour therapy techniques 
such as self-monitoring, guided-discovery, life-style adjustment, cognitive re-appraisal.[52] The nurse 
will invite patients to examine their lifestyle prior to their prostate cancer diagnosis, identify how their 
thoughts, ideas, feelings, attitudes and behaviours affect their day-to-day life, and to reflect on the 
impact this is having on their life. For patients who have fully adjusted to survivorship, the process is 
expected to be relatively quick and seamless. However, patients who experience any level of unmet 
need will firstly benefit from the guided self-reflection.[53] Secondly, where action is necessary to 
address individual symptoms, patients will be offered specific and personalised advice. Supported by 
the nurse, patients will consider which aims and strategies are attainable and relevant for their 
circumstances. A plan will be devised together with the nurse to accomplish these goals, and will be 
documented in the personalised care plan. A copy of the initial holistic needs assessment summary 
and the complete personalised plan of care will be given to patients and with their consent will be sent 
to their GP for information and long-term management. A covering letter will explain to GPs the 
context of the care plan, the scope and duration of the intervention and will provide a point of contact 
for any related queries. Where the level of support and complexity of need will exceed the capability 
of the current intervention, the nurse will specifically refer patients to their GP or for specialist 
support, as appropriate. 
The follow-up sessions. By agreement with patients, the nurse will arrange follow-up 
appointments to monitor the progress of the self-management strategies advised during the initial 
assessment. The progress made and any related patient concerns will be documented in the patient’s 
plan of care and again shared with patients and their GP as before. The accompanying covering letter 
will inform GPs of the remaining support available from the intervention and the outstanding patient 
needs and concerns. Patients will also be given the opportunity to request follow-up sessions at any 
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point during the intervention by contacting the nurse by telephone. As above, follow-up appointments 
will take place in general practice, community hospital, the research unit, or at the patient’s home, for 
housebound patients. These appointments will be in addition to any referrals to support outside the 
intervention. We anticipate men will need on average 1-2 follow-up sessions, but their number will 
not be limited. The frequency, setting and content of these sessions will be recorded by the nurse for 
the process evaluation. 
 Outcome measures 
 As a phase II trial, the primary measures of interest are patient recruitment, attrition and 
response rate for questionnaires. To capture the intervention outcome, a battery of established 
patient reported measures will be used to assess changes in the physical symptoms (EPIC-26, 
Expanded Prostate Cancer Index Composite),[54] psychological wellbeing (Hospital Anxiety and 
Depression Scale),[55] confidence in managing own health,[56] medical and support needs 
(Supportive Care Needs Survey – simplified response format),[57-58] general health and quality of life 
(EuroQoL EQ-5D-5L),[59] and a bespoke questionnaire assessing patients’ satisfaction with the 
healthcare services. To reduce participant burden, the questionnaires have been collated in a single 
booklet. All questionnaires will be self-completed by patients. The researcher recruiting the patients 
will offer the baseline measures to all patients after consent, and prior to randomisation. The 
researcher will remain blind to the randomisation results until the end of recruitment. Subsequent 
questionnaires will be sent by post to be completed by patients in both arms and similarly returned to 
the research team by post (see Table 2).
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Table 2. Timeline of intervention delivery and outcome measures 
 Augmented Usual Care Nurse-led Intervention 
T0 T1 T2 T3 T0 T1 T2 T3 
Consent 12 weeks 24 weeks 36 weeks Consent 12 weeks 24 weeks 36 weeks 
Follow-up 
care 
Macmillan organiser         
Routine signposting to Macmillan 
information centre, GP, hospital services 
        
Ongoing follow-up appointments    
Holistic need assessment      
Follow-up appointments      
Outcome 
measures 
EPIC-26, HADS, SCNS-34, EQ-5D-5L, 
confidence in managing own health, 
satisfaction with health care services 
        
Health service use diary         
Feedback interview         
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 The ongoing use of health and social care services during the intervention will be collected at 
12, 24 and 36 weeks using a purpose-built diary. The questionnaire documents the frequency and 
types of contacts with primary and secondary healthcare services, social services, and voluntary 
sector services. The diary will include information about: the number of times the patient had to see 
a doctor, nurse, or other healthcare professional in relation to his prostate cancer related symptoms; 
the special medication, aids, and adaptations prescribed to patients to help with their prostate 
cancer related symptoms; the number of days patients felt too unwell to participate in their normal 
activities due to prostate cancer related symptoms. Moreover, relevant medical history data (e.g., 
cancer diagnosis, stage, treatment type, chronic and acute comorbid conditions, etc.) will be 
collected from GP-and hospital-held records with patients’ consent. 
 A sub-sample of patients in the intervention group (N=32), the research nurse, and 
secondary and primary care clinicians (N=10) will be invited to take part in individual feedback 
interviews, at the end of the trial. Patients will be selected through purposive sampling to include all 
types of treatment (surgery, radiotherapy, hormone therapy, watchful waiting), cancer stage 
(localised, locally advanced/advanced), and represent a balanced median split for age and level of 
need. Clinicians will be selected from those who had the largest number of patients in trial. A 
researcher not involved in the intervention delivery will conduct the interviews face-to-face, or 
alternatively by telephone. The interviews will be semi-structured and investigate the patients’ 
experience of the intervention, the perceived benefits and missed opportunities of the trial, and 
possible effects beyond those captured in the proposed outcome measures (both for patients and 
healthcare services/clinicians). 
 Data safety and monitoring 
The study procedure and intervention were assessed to present only low impact risks for 
patient safety, with a low probability. Thus, an independent data monitoring group will not be 
needed, and interim analyses will not be conducted. However, the intervention will be continuously 
monitored for safety by the research team, with direct input from the patients’ general practice and 
referring secondary care clinicians. All process and safety monitoring records will be maintained in 
accordance with national and local research governance regulations. All adverse events and serious 
adverse events will be recorded and followed up for the duration of the study or until resolution. 
Assessment of adverse events will be performed by the clinical lead of the research team. All serious 
adverse events will be graded and reported to the sponsor, funder, and the ethics and research 
governance committees. 
 Data management 
 All data will be collected on paper questionnaires, which will be stored, linked and entered 
electronically in an anonymised format. Routine data checks will be performed at two time points: 
(1) when the questionnaires are received from patients, and (2) when the data is entered into a 
secure electronic data capture system (MACRO, version 4.2.4, InferMed Limited), hosted and 
managed by the clinical trials unit (NWORTH). Electronic data will be audited on an ongoing basis by 
two independent auditors, and outcomes will inform the remaining data collection and entry. All 
data queries will be managed directly by a single Data Manager, and the complete audit trail will be 
recorded electronically in MACRO. At the end of the trial, all paper questionnaires and electronic 
data will be archived securely, and stored for 5 years, after which they will be confidentially 
destroyed. 
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Data analysis 
Feasibility metrics (e.g., recruitment and retention rates, clinical characteristics, 
randomisation, duration of the intervention, etc.) will be analysed first together with adherence 
outcomes (patient acceptance and adherence to the intervention). Medical history data will be 
assessed for completeness in conjunction with the outcome measures. The semi-structured 
interviews will be analysed using the matrix based thematic Framework approach which facilitates 
analysis both by case and theme.[60-61] 
A preliminary analysis of the intervention outcomes will be carried out, following an 
intention-to-treat approach. Point and 95% confidence interval estimates will be calculated for the 
changes in prostate specific symptoms, quality of life, psychological wellbeing, self-confidence in 
managing own health, and ongoing medical and support needs between the two groups. Results will 
be used to estimate standard deviations and effect sizes to help inform a sample size calculation for 
a future phase III RCT – if feasibility and acceptability are confirmed.  
The analysis will also address the health economics of the intervention. The benefit 
measurement will use both generic health related quality of life (EQ-5D-5L), and prostate cancer 
specific quality of life measures. The analysis will take a societal perspective given the broad impact 
on the NHS (both primary and secondary care), the patients, their families, and the third sector. In 
line with established guidelines for economic evaluation of complex interventions,[62] the costing 
analysis will use the national unit costs.[63] The outcome of the preliminary economic analysis 
estimates will serve to develop the protocol for a full primary cost utility analysis, with a secondary 
cost consequence analysis, in a future phase III RCT.  
 
Discussion 
 The TOPCAT-P trial proposes a novel model of care for prostate cancer survivors, in line with 
recent NICE guidelines, local government health policy, and charity sector initiatives in Wales, to 
offer a holistic and personalised care delivered in primary and community care settings. These 
changes to presently hospital-based models of care come in response to increased levels of patient 
unmet need, raising numbers of prostate cancer survivors with continuing upward estimates, and 
unavoidable logistical and financial pressures on secondary care teams. 
The present trial aims to evaluate the feasibility and acceptability of the intervention, 
addressing the wider group of cancer survivors, using the novel holistic needs assessment and care 
planning tools, in the context of care in Wales. The results will inform the design of a definitive stage 
III trial, for this model of prostate cancer follow-up. A phase III RCT would be deemed feasible if: (1) 
a minimum of 25% of the clinically eligible patients, who will be invited to take part in the trail are 
recruited, (2) the attrition rate during the trial is no greater than 20%, and (3) the outcome measures 
completion rate for the active participants (i.e., those who have not withdrawn, died or been lost to 
follow-up) is above 66%. All the feasibility metrics will be calculated using 95% confidence intervals. 
Moreover, the patients’ and clinicians’ feedback will be used to assess the acceptability of the 
intervention and shape its future administration as well as the overall communication with 
participants and healthcare professionals. The recruitment, attrition and questionnaire completion 
rates, together with the standard deviation of the main intervention outcomes will inform the 
estimation of the sample size for a future phase III trial. The time needed to collect and analyse the 
data will be used to determine the optimum timings of each activity, and the overall duration of the 
trial. 
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 The nurse-led intervention piloted in TOPCAT-P is based on a similar trial conducted in 
England (PROSPECTIV),[38] but is significantly different in three methodological areas, which will 
extend the knowledge gained from PROSPECTIV and assess the feasibility and acceptability of the 
intervention in a different area and settings. Firstly, the intervention is offered to stable prostate 
cancer survivors irrespective of their self-reported level of need. Secondly, the holistic needs 
assessment, care planning and information sharing documentation is based on novel instruments 
currently being considered for routine clinical use in the TOPCAT-P recruitment area. Thirdly, the 
definition of usual care is updated in response to on-going changes to practice in Wales including 
new routine third sector improvements, which will provide a contextualised assessment of the 
intervention’s effects. However, similarly with PROSPECTIV, the intervention is nurse-led, based on a 
psycho-educational framework, promotes self-management of symptoms, is delivered in the 
community, and includes patients’ close social group (e.g., partner, family, carers) where this is 
relevant and helpful for the patient. 
 
Strengths and limitations 
- The intervention is designed in line with new Welsh health policy by promoting prudent 
healthcare principles and offering a key worker for each cancer survivor. 
- The holistic needs assessment uses novel and comprehensive instruments bridging research 
and hospital best practice, which will be shared with patients, primary and secondary care. 
- The study adopts an augmented form of usual care, in line with ongoing developments of 
the care system in the recruitment area. 
- The intervention is offered to stable survivors, irrespective of risk-stratification, or self-
reported level of need, for an accurate assessment of its overall effectiveness. 
- Recruitment area covers both rural and urban regions, with a wide mix of socio-economic 
strata 
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